Why āshibio’s 40,000-patient ADO2 market estimate requires careful interpretation
āshibio's vantictumab activates bone resorption in 94% of patients. New ADO2 prevalence findings sharpen its clinical and safety questions.
Pharma & Biotech
Pharma & Biotech
Can āshibio’s andecaliximab stop abnormal bone growth? An 86.2% flare-up reduction raises the stakes
āshibio reports 86.2% fewer FOP flare-ups with andecaliximab in early data, but placebo-controlled evidence remains pending.